Should acute myeloid leukemia patients with actionable targets be offered investigational treatment after failing one cycle of standard induction therapy

摘要: Purpose of review Therapeutic failure in acute myeloid leukemia remains common. It may be advantageous to identify patients with suboptimal treatment responses early as they benefit from timely care strategy changes. Here, portending standard induction therapy are reviewed and therapeutic options examined, including use investigational, targeted agents for suitable patients. Recent findings Patients entering complete remission without minimal residual disease early, that is, one cycle chemotherapy, have a lower relapse risk live longer than other similarly-treated patients, supporting the proposition criterion success. Investigational small molecule drugs appealing who fail therapies, but rates single agent typically modest. Summary The relative value different strategies if first fails produce is unknown. However, retreatment same often leads provides benchmark against which approaches should compared. Addition investigational reinduction actionable targets could offer an attractive this situation might improve outcomes facilitate clinical drug testing.